Samsrita Labs Ltd Board Approves Capital Reduction and Appoints New Director

Samsrita Labs Ltd Board Approves Capital Reduction and Appoints New Director​

Samsrita Labs Limited, on July 4, 2026, announced several material outcomes from its Board of Directors meeting, including the appointment of an additional director, a scheme for capital reduction, and significant changes to the company's core business objectives.

The Board meeting also considered and approved proposals for a related party transaction with QROPS Advisory Services Private Limited, an associate company. Additionally, directors reviewed the financial performance for the Financial Year 2025-26, and the notice was issued for the Annual General Meeting (AGM) scheduled for August 10, 2026.

Capital Restructuring Details​

A key decision taken by the Board is the proposal for a Scheme of Reduction of Capital of the company’s Issued, Subscribed, and Paid-up Share capital. The reduction is intended to reorganize the equity capital structure and set off accumulated losses.

Under the proposed scheme, 11,37,48,550 fully paid-up equity shares, each at a face value of Rs. 10, are scheduled for cancellation on a pro-rata basis. This restructuring is being undertaken to address past accumulated losses and simplify the capital structure.

The capital reduction will transition the company's paid-up equity share capital from an initial amount of Rs. 22,74,97,100 (comprising 2,27,49,710 shares of Rs. 310 each) to a reduced capital base of Rs. 11,37,48,550 (comprising 1,13,74,855 shares of Rs. 310 each).

The cancelled shares are intended to be set off against accumulated losses and share premium balance, which total ¥11,57,66,110/-. This move aims to improve the net worth of the company by eliminating a substantial portion of past losses. The scheme will not accrue any benefit to the promoter or promoter group companies.

A summary of the financial impact of the restructuring is provided below:

Director Appointment and Business Expansion​

The Board also approved the appointment of Mr. Ravi Kanth Naga Pattabhi Chopperla as an Additional Director of the company in the category of Professional and Non-Executive, effective July 4, 2026.

Mr. Ravikanth Chopperla is noted for his extensive experience across corporate governance and financial services, holding over 18 years of experience in investor relations, business transformation, and advisory. He currently serves as Executive Director & Chief Operating Officer of QROPS Advisory Services (QAS) Private Limited and holds a Non-Executive Directorship at ECI Systems Private Limited. Mr. Chopperla possesses an MBA in Marketing from Dravidian University and holds the status of a Certified Independent Director. He holds a 7.1% stake, owning 16,16,001 equity shares in the company.

Furthermore, the Board sanctioned an alteration to the existing Main Object Clause of the Memorandum of Association. This modification includes the insertion of a new sub-clause that allows the company to engage in pet animal healthcare and wellness. This expanded business scope involves providing veterinary, diagnostic, preventive, curative, therapeutic, rehabilitation, grooming, nutrition, and allied services for pet and companion animals. The company is authorized to manufacture, formulate, and deal in various products related to this sector, including veterinary medicines, pharmaceuticals, nutraceuticals, and pet foods.

Annual General Meeting Details​

The AGM for the Financial Year 2025-26 has been scheduled to be held on Monday, August 10, 2026, at 11:00 AM via video conference or other Audio-visual means (OAVM). The cut-off date set for the purpose of the AGM is Monday, August 3, 2026.

Stock Price Movement​

Samsrita Labs Ltd closed on Friday trading lower, settling at ₹11.70, which was down 0.34%. Shares traded within a wide intraday band, achieving a high of ₹12.32 but subsequently dipping as low as ₹11.20 during the session.